Top

Published in:

01-12-2021 | Dementia | Original Article

Serum transthyretin and risk of cognitive decline and dementia: 22-year longitudinal study

Authors: Marzieh Araghi, Martin J. Shipley, Atul Anand, Nicholas L. Mills, Mika Kivimaki, Archana Singh-Manoux, Adam Tabák, Séverine Sabia, Eric J. Brunner

Published in: Neurological Sciences | Issue 12/2021

Abstract

Serum transthyretin (TTR) may be an early biomarker for Alzheimer’s disease and related disorders (ADRD). We investigated associations of TTR measured at baseline with cognitive decline and incident ADRD and whether TTR trajectories differ between ADRD cases and non-cases, over 22 years before diagnosis. A total of 6024 adults aged 45–69 in 1997–1999 were followed up until 2019. TTR was assessed three times, and 297 cases of dementia were recorded. Higher TTR was associated with higher cognitive function at baseline; however, TTR was unrelated to subsequent change in cognitive function. TTR at baseline did not predict ADRD risk (hazard ratio per SD TTR (4.8 mg/dL) = 0.97; 95% confidence interval: 0.94–1.00). Among those later diagnosed with ADRD, there was a marginally steeper downward TTR trajectory than those free of ADRD over follow-up (P=0.050). Our findings suggest TTR is not neuroprotective. The relative decline in TTR level in the preclinical stage of ADRD is likely to be a consequence of disease processes.

Available only for authorised users

Collaborators GBDD (2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(1):88–106. https://doi.org/10.1016/S1474-4422(18)30403-4CrossRef

Kumar A, Singh A, Ekavali (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 67(2):195–203. https://doi.org/10.1016/j.pharep.2014.09.004CrossRefPubMed

Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA (2007) Transthyretin and Alzheimer’s disease: where in the brain? Neurobiol Aging 28(5):713–718. https://doi.org/10.1016/j.neurobiolaging.2006.03.015CrossRefPubMed

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562. https://doi.org/10.1016/j.jalz.2018.02.018CrossRefPubMedPubMedCentral

Alemi M, Gaiteiro C, Ribeiro CA, Santos LM, Gomes JR, Oliveira SM, Couraud PO, Weksler B, Romero I, Saraiva MJ, Cardoso I (2016) Transthyretin participates in beta-amyloid transport from the brain to the liver--involvement of the low-density lipoprotein receptor-related protein 1? Sci Rep 6:20164. https://doi.org/10.1038/srep20164CrossRefPubMedPubMedCentral

Corcoran JP, So PL, Maden M (2004) Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 20(4):896–902. https://doi.org/10.1111/j.1460-9568.2004.03563.xCrossRefPubMed

Delliere S, Cynober L (2017) Is transthyretin a good marker of nutritional status? Clin Nutr 36(2):364–370. https://doi.org/10.1016/j.clnu.2016.06.004CrossRefPubMed

Giao T, Saavedra J, Cotrina E, Quintana J, Llop J, Arsequell G, Cardoso I (2020) Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer’s disease. Int J Mol Sci 21(6). https://doi.org/10.3390/ijms21062075

Tien YT, Lee WJ, Liao YC, Wang WF, Jhang KM, Wang SJ, Fuh JL (2019) Plasma transthyretin as a predictor of amnestic mild cognitive impairment conversion to dementia. Sci Rep 9(1):18691. https://doi.org/10.1038/s41598-019-55318-0CrossRefPubMedPubMedCentral

10.

Velayudhan L, Killick R, Hye A, Kinsey A, Guntert A, Lynham S, Ward M, Leung R, Lourdusamy A, To AW, Powell J, Lovestone S (2012) Plasma transthyretin as a candidate marker for Alzheimer’s disease. J Alzheimers Dis 28(2):369–375. https://doi.org/10.3233/JAD-2011-110611CrossRefPubMed

11.

Marmot M, Brunner E (2005) Cohort Profile: the Whitehall II study. Int J Epidemiol 34(2):251–256. https://doi.org/10.1093/ije/dyh372CrossRefPubMed

12.

Pasella S, Baralla A, Canu E, Pinna S, Vaupel J, Deiana M, Franceschi C, Baggio G, Zinellu A, Sotgia S, Castaldo G, Carru C, Deiana L (2013) Pre-analytical stability of the plasma proteomes based on the storage temperature. Proteome Sci 11(1):10. https://doi.org/10.1186/1477-5956-11-10CrossRefPubMedPubMedCentral

13.

Sommerlad A, Sabia S, Singh-Manoux A, Lewis G, Livingston G (2019) Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study. PLoS Med 16(8):e1002862. https://doi.org/10.1371/journal.pmed.1002862CrossRefPubMedPubMedCentral

14.

Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimaki M, Singh-Manoux A (2017) Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ 357:j2709. https://doi.org/10.1136/bmj.j2709CrossRefPubMedPubMedCentral

15.

Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF (2008) Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol 64(5):492–498. https://doi.org/10.1002/ana.21509CrossRefPubMed

16.

Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P, Shipley MJ, Muniz-Terrera G, Singh-Manoux A, Kivimaki M, Steptoe A, Capewell S, O'Flaherty M, Brunner EJ (2017) Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. BMJ 358:j2856. https://doi.org/10.1136/bmj.j2856CrossRefPubMedPubMedCentral

17.

Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O (2020) Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 26(3):379–386. https://doi.org/10.1038/s41591-020-0755-1CrossRefPubMed

18.

Cascella R, Conti S, Mannini B, Li X, Buxbaum JN, Tiribilli B, Chiti F, Cecchi C (2013) Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim Biophys Acta 1832(12):2302–2314. https://doi.org/10.1016/j.bbadis.2013.09.011CrossRefPubMed

19.

Giunta S, Valli MB, Galeazzi R, Fattoretti P, Corder EH, Galeazzi L (2005) Transthyretin inhibition of amyloid beta aggregation and toxicity. Clin Biochem 38(12):1112–1119. https://doi.org/10.1016/j.clinbiochem.2005.08.007CrossRefPubMed

20.

Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, Wright PE, Kelly JW, Buxbaum JN (2013) Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. J Neurosci 33(50):19423–19433. https://doi.org/10.1523/JNEUROSCI.2561-13.2013CrossRefPubMedPubMedCentral

21.

Mangrolia P, Murphy RM (2018) Retinol-binding protein interferes with transthyretin-mediated beta-amyloid aggregation inhibition. Biochemistry 57(33):5029–5040. https://doi.org/10.1021/acs.biochem.8b00517CrossRefPubMed

22.

Martorana A, Di Lorenzo F, Belli L, Sancesario G, Toniolo S, Sallustio F, Sancesario GM, Koch G (2015) Cerebrospinal Fluid Abeta42 Levels: When physiological become pathological state. CNS Neurosci Ther 21(12):921–925. https://doi.org/10.1111/cns.12476CrossRefPubMedPubMedCentral

23.

Martorana A, Di Lorenzo F, Manenti G, Semprini R, Koch G (2014) Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals. Front Aging Neurosci 6:254. https://doi.org/10.3389/fnagi.2014.00254CrossRefPubMedPubMedCentral

24.

Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzheimers Dis 16(2):389–397. https://doi.org/10.3233/JAD-2009-0966CrossRefPubMed

25.

Ribeiro CA, Santana I, Oliveira C, Baldeiras I, Moreira J, Saraiva MJ, Cardoso I (2012) Transthyretin decrease in plasma of MCI and AD patients: investigation of mechanisms for disease modulation. Curr Alzheimer Res 9(8):881–889. https://doi.org/10.2174/156720512803251057CrossRefPubMed

26.

Han SH, Jung ES, Sohn JH, Hong HJ, Hong HS, Kim JW, Na DL, Kim M, Kim H, Ha HJ, Kim YH, Huh N, Jung MW, Mook-Jung I (2011) Human serum transthyretin levels correlate inversely with Alzheimer's disease. J Alzheimers Dis 25(1):77–84. https://doi.org/10.3233/JAD-2011-102145CrossRefPubMed

27.

Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer’s disease and non-demented elderly subjects. Neurol Res 28(2):155–163. https://doi.org/10.1179/016164106X98035CrossRefPubMed

28.

Buxbaum J, Koziol J, Connors LH (2008) Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid 15(4):255–261. https://doi.org/10.1080/13506120802525285CrossRefPubMedPubMedCentral

29.

Buxbaum J, Anan I, Suhr O (2010) Serum transthyretin levels in Swedish TTR V30M carriers. Amyloid 17(2):83–85. https://doi.org/10.3109/13506129.2010.483118CrossRefPubMed

Title: Serum transthyretin and risk of cognitive decline and dementia: 22-year longitudinal study
Authors: Marzieh Araghi
Martin J. Shipley
Atul Anand
Nicholas L. Mills
Mika Kivimaki
Archana Singh-Manoux
Adam Tabák
Séverine Sabia
Eric J. Brunner
Publication date: 01-12-2021
Publisher: Springer International Publishing
Keywords: Dementia
Dementia
Biomarkers
Published in: Neurological Sciences / Issue 12/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05191-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum transthyretin and risk of cognitive decline and dementia: 22-year longitudinal study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2021

Clinical predictors for mechanical ventilation and prognosis in patients with Guillian-Barre syndrome: a 10-year experience

Multidimensional predicting model of intracranial aneurysm stability with backpropagation neural network: a preliminary study

Narrative Medicine to integrate patients’, caregivers’ and clinicians’ migraine experiences: the DRONE multicentre project

Driving and Alzheimer’s dementia or mild cognitive impairment: a systematic review of the existing guidelines emphasizing on the neurologist’s role

Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection

The relationship between attention and static balance disturbance in patients with Parkinson’s disease